Atogepant

7 trials 3 recruiting

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

3 Recruiting

4 Completed trials

1 Sponsors

15 Countries

Phase III

Phase III: 7

Oversight events:

10 temporary halts 7 corrective measures across 6 trials

View oversight register →

Indications tested

Migraine without aura 5 Migraine with aura 5 Migraine 3 Migraine prophylaxis 1

Sponsors using this IMP

AbbVie Deutschland GmbH & Co. KG 7

All trials

7 total

Long-term Extension Study to Assess Adverse Events and Tolerability of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Ag… Recruiting

2022-501099-24-00 Phase III 11 countries Abbvie Deutschland GmbH & Co. KG
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) … Recruiting

2022-501100-94-00 Phase III 10 countries Abbvie Deutschland GmbH & Co. KG
A Study to Assess the Adverse Events and Change in Disease Activity of Atogepant Oral Tablets in Pediatric Participants with Chronic Migrain… Recruiting

2024-513836-28-00 Phase III 6 countries AbbVie Deutschland GmbH & Co. KG
A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended

2024-512946-41-00 Phase III 7 countries AbbVie Deutschland GmbH & Co. KG
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Phase III 10 countries AbbVie Deutschland GmbH & Co. KG
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended

2022-501172-25-00 Phase III 9 countries Abbvie Deutschland GmbH & Co. KG
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine Ended

2023-507096-21-00 Phase III 9 countries AbbVie Deutschland GmbH & Co. KG

Showing 1–7 of 7 trials

← All drugs A–Z